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Abstract
Background: The Patient Health Questionnaire PHQ-9 is a widely used instrument to screen for depression in
clinical research. The first aim of this study was to psychometrically test the PHQ-9 in a large sample of cancer
patients. The second aim was to calculate unbiased estimates of the depression burden for several cancer groups
taking into account age and gender distributions.
Methods: A sample of 2,059 cancer patients with varying diagnoses were examined in this study six months after
discharge from a rehabilitation clinic. A representative sample of 2,693 people from the general population served
as controls. Expected PHQ-9 mean scores of the general population sample, regressed on age and gender, were
calculated to enable a fair comparison of different groups of cancer patients.
Results: While the reliability (Cronbach’s alpha) for the PHQ-9 scale was good (alpha ≥ 0.84), the CFA fit indices of
the one-dimensional solution were unsatisfactory in the patients’ sample. The factorial analysis confirmed two
factors. PHQ-9 mean scores for 15 types of cancer are given, ranging from 4.0 (prostate) to 8.2 (thyroid gland).
Differences between expected mean scores (derived from the general population) and raw mean scores of the
cancer subsamples are reported that provide a better estimate of the depression burden.
Conclusions: The results confirmed that the PHQ-9 performs well in testing depression in cancer patients. Regression
coefficients can be used for performing unbiased comparisons among cancer groups, not only for this study. The
burden of patients with testis cancer and Hodgkin lymphoma is underestimated when age and gender are not taken
into account.
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Background
Depression is frequently observed in cancer patients. Meta-
analyses reported a 25 % prevalence of all types of depres-
sion among cancer patients [1] and a 32 % prevalence of
mental health conditions in general [2]. Depression may
negatively affect treatment outcomes [3] and can be associ-
ated with elevated mortality in cancer patients [4].
Oncologists often fail to detect depression in their pa-
tients [5, 6]. Therefore, it is important to use standard-
ized and easily applicable tools to detect depression.
There are several screening instruments that proved to
be effective for that purpose. The most often used ques-
tionnaires measuring depression in cancer patients are
the Hospital Anxiety and Depression Scale HADS [7],
the Beck Depression Inventory BDI [8] and the Center
for Epidemiologic Studies Depression Scale CES-D [9],
for a new summarizing review cf. [10]. A further, freely
available and more recently developed questionnaire is
the Patient Health Questionnaire PHQ-9 [11]. Its valid-
ity has been proven in several studies [12–15]. Norma-
tive scores are available [16], and two studies supply
tools for converting scores between PHQ-9 and other
depression scales [17, 18]. The PHQ-9 is generally used
in its original one-dimensional form (sum score of the 9
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items), but several psychometric studies with multiple
disease groups challenged the one-dimensional solution
[19, 20] and showed that two-dimensional solutions fit-
ted better [21–25]. The assignments of the items to
these two factors were not totally identical in these stud-
ies, but all of them obtained one factor concentrating on
emotional and cognitive aspects (depressed mood, feel-
ing worthless, and thoughts of death), and the other on
somatic aspects (sleep problems, loss of energy, and ap-
petite problems). The first central aim of this study was
to test whether such a two-dimensional solution could
also be found in a sample of cancer patients. In particu-
lar, we test the specific two-dimensional model that per-
formed best in three [22, 23, 25] of the five [21–25]
studies. In addition, the psychometric properties of the
items in terms of item-test correlations and the correla-
tions with other scales on emotional and somatic factors
were to be examined.
Furthermore, there are age and gender differences in-
fluencing the PHQ-9 scores in the general population
[16]. These differences should be taken into account
when comparing patients with different cancer locations.
It has often been documented that depression is rela-
tively high in breast cancer patients [26] and low in
prostate cancer patients [27]. However, to what degree is
this difference due to different age and gender distribu-
tions? Unbiased comparisons between cancer groups can
be done by calculating expected mean scores from the
general population using linear regression analyses, cf.
[28], and by considering the differences between the pa-
tients’ group means and these expected mean scores de-
rived from the general population. The second objective
of this study was to perform such regression analyses
and compare the mean depression levels for multiple
cancer types with and without correction for age and
gender effects.
In summary, the aims of this paper were
– to test psychometric properties and the factorial
structure of the PHQ-9,
– to calculate a regression analysis for the assessment
of expected mean scores that help evaluate the
PHQ-9 mean values of different cancer entities, and
– to calculate unbiased estimates of the depression
burden for several cancer diagnoses.
Methods
Cancer patients
Between 2011 and 2012, a group of 3,592 consecutive
patients treated in a German rehabilitation clinic were
asked to participate in the study. In Germany, most cancer
patients are offered the opportunity to participate in re-
habilitation program to regain physical and psychosocial
functioning. During that program, generally lasting three
weeks, the patients receive physiotherapy, physical fitness
exercises, relaxation techniques, counseling concerning
nutritional and occupational issues, and coping training.
Inclusion criteria were age 18 years and above, absence of
severe cognitive impairment, and sufficient command of
the German language. Written informed consent was ob-
tained from the study participants after full explanation of
the purpose and nature of the data collection and storage.
This research meets the ethics guidelines of the institution
where the study was performed, including adherence to
the legal requirements of Germany. A total of 2909
(81.0 %) of the 3,592 candidates agreed to participate in
the study. These patients were sent a letter with several
questionnaires six months after being discharged from the
rehabilitation clinic. In all, 2059 patients responded
(57.3 % of all patients; 72.4 % of the patients receiving the
letter). Table 1 presents characteristics of the sample.
General population
The data basis for the control group was a survey of the
German general population (age 14 to 92 years), con-
ducted in two waves: in 2003 (n = 2,500) and in 2008 (n
= 2,518). Age, gender, and regional distribution were the
major criteria for representativeness. The random-route
procedure included random selection of sample points
within Germany, random selection of houses and house-
hold within these areas, and random selection of the tar-
get person within the household. The summarized
response rate was 63 %; 5,018 subjects (54 % females)
participated in the study. Written informed consent was
obtained by all study participants. In order to allow for a
fair comparison with the patient sample, we selected a
subsample so that the age and gender distribution
matched that of the patients. The final sample of the
general population comprised 2,693 subjects between 40
and 92 years, mean age: 62.3 (SD = 11.3) years; 1,579
males (59 %) and 1,114 females (41 %), in accordance
with the distribution of the patients’ sample. The aims of
the general population studies were to obtain normative
values for several questionnaires. Further details of the
studies have been reported elsewhere [16]. The study




The PHQ-9 is a screening instrument with 9 items (see
Table 2), developed to measure depression. For each
item the patients are asked to assess how much they
were bothered by the symptoms over the last two weeks.
There are four answer options: not at all (0), several days
(1), more than half of the days (2), and nearly every day
(3). The sum score (range 0 to 27) indicates the degree
of depression, with scores of ≥5, ≥10, and ≥15
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representing mild, moderate, and severe levels of depres-
sion [11]. While the PHQ-9 was used in both the pa-
tients’ and the general population group, the further
questionnaires (see below) were only administered to the
patients’ group.
EORTC QLQ-C30
The quality of life questionnaire EORTC QLQ-C30 [29]
consists of 30 items and incorporates five functioning
scales (physical, role, emotional, social, and cognitive),
three symptom scales (fatigue, pain and nausea/vomit-
ing), a global health status/QoL scale and six single
items. Higher functioning scores represent better func-
tioning/QoL, whereas higher symptom scores represent
more severe symptoms.
FoP
The 12-item Fear of Progression Questionnaire is a short
form of the original 43-item Fear of Progression instru-
ment [30] designed to assess fear of cancer progression.
The items are scored on a five-point Likert scale, ran-
ging from 1 (‘never’) to 5 (‘very often’), resulting in a
sum score from 12 to 60.
GAD-2
The Generalized Anxiety Disorder Questionnaire GAD-
2 is a 2-item short form of the GAD-7 [31]. Together
with the PHQ-2, the GAD-2 forms the PHQ-4 [32]. The
answer options are identical to those of the PHQ-9.
Statistical analyses
Means, standard deviations, reliability coefficients
(Cronbach’s alpha) and part-whole-corrected item-test-
correlations were calculated. Mean score differences
were expressed in terms of effect sizes d according to
Cohen [33]. Principal component analyses (PCA) with







N % N % N %
Age Mean (SD) in years 62.4 (14.2) 64.8 (11.9) 59.1 (16.4)
Age category
18-35 y. 141 6.8 53 4.4 88 10.4
36-45 y. 138 6.7 30 2.5 108 12.7
46-55 y. 233 11.3 108 8.9 125 14.7
56-65 y. 498 24.2 333 27.5 165 19.4
66-75 y. 788 38.3 544 45.0 244 28.7
76-94 y. 261 12.7 142 11.7 119 14.0
Diagnosis
Prostate 640 31.1 640 52.9 0 0.0
Breast 346 16.8 3 0.2 343 40.4
Colon 196 9.5 91 7.5 105 12.4
Kidney 119 5.8 68 5.6 51 6.0
Bladder 91 4.4 71 5.9 20 2.4
Rectum 90 4.4 56 4.6 34 4.0
Hodgkin lymphoma 64 3.1 28 2.3 36 4.2
Stomach 53 2.6 35 2.9 18 2.1
Ovary 41 2.0 0 0.0 41 4.8
Testis 35 1.7 35 2.9 0 0.0
Other non-Hodgkin lymphoma 31 1.5 17 1.4 14 1.6
Pancreas 31 1.5 21 1.7 10 1.2
Oesophagus 30 1.5 26 2.1 4 0.5
Non-follicular lymphoma 30 1.5 16 1.3 14 1.6
Thyroid gland 29 1.4 8 0.7 21 2.5
Others 233 11.3 95 7.9 138 16.3
Number of tumors
1 1,851 89.9 1,084 89.6 767 90.3
≥2 208 10.1 126 10.4 82 9.7
Surgery
no 208 10.1 110 9.1 98 11.5
yes 1,851 89.9 1,100 90.9 751 88.5
Radiation
no 1,424 69.2 973 80.4 451 53.1
yes 635 30.8 237 19.6 398 46.9
Chemotherapy
no 1,326 64.4 908 75.0 418 49.2
yes 733 35.6 302 25.0 431 50.8
Endocrine therapy
no 1,782 86.5 1,142 94.4 640 75.4
yes 277 13.5 68 5.6 209 24.6
Antibody therapy
no 1,934 93.9 1,166 96.4 768 90.5
yes 125 6.1 44 3.6 81 9.5
Table 2 Mean scores of the PHQ-9 items and the sum score for
cancer patients and the general population
Item Patients General population d
M SD M SD
1 Loss of interest 0.71 0.73 0.52 0.63 0.30
2 Feeling depressed 0.59 0.70 0.38 0.60 0.35
3 Sleep problems 1.07 0.95 0.63 0.75 0.59
4 Loss of energy 0.97 0.78 0.65 0.70 0.46
5 Appetite problems 0.45 0.75 0.28 0.56 0.30
6 Self-blame 0.33 0.61 0.20 0.48 0.27
7 Concentration problems 0.64 0.71 0.39 0.60 0.42
8 Agitation/retardation 0.35 0.64 0.16 0.45 0.42
9 Suicidal ideation 0.15 0.43 0.10 0.35 0.14
Sum score 5.26 4.27 3.30 3.65 0.54
d, effect size
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two factors and varimax rotation were performed since
previous studies also detected two-dimensional struc-
tures [21, 22]. Confirmatory factorial analyses (CFA) [34]
were performed with Mplus. We used the following cri-
teria: Bayesian Information Criterion (BIC), Standardized
Root Mean Square Residual (SRMR), Root Mean Square
Error of Approximation (RMSEA) [35], Comparative Fit
Index (CFI) [36], and Tucker Lewis Index (TLI) [37].
RMSEA should be lower than 0.10, and CFI and TLI
should be greater than or equal to 0.95 [34].
A linear regression analysis of the general population’s
sample was performed, with age and gender as inde-
pendent variables and the PHQ-9 sum score as the
dependent variable. Expected PHQ-9 mean scores were
calculated with these regression coefficients for several
cancer groups, depending on their age and gender distri-
butions. These expected mean scores were then com-
pared with the raw mean scores of the cancer groups.
Results
Mean scores of the PHQ-9 items
The mean sum score of the PHQ-9 in the patients’ sam-
ple was 5.26 (Table 2). According to the cut-off criteria
for mild (5–9), moderate (10–14), and severe (≥15) de-
pression, the frequencies were 49.8 % (no), 35.1 % (mild),
11.3 % (moderate), and 3.7 % (severe) depression for the
patients. In the general population, the percentages for
no, mild, moderate, and severe depression were 72.2 %,
21.2 %, 5.1 %, and 1.5 %, respectively.
On the item level, the mean scores (Table 2) of the
cancer sample ranged from 0.15 (suicidal ideation) to
1.07 (sleep problems). All items showed higher mean
scores in the cancer group compared with the general
population. The greatest differences between both sam-
ples, expressed in terms of effect sizes (d > 0.40), were
found for items 3 (sleep problems), 4 (loss of energy), 7
(concentration problems), and 8 (psychomotor agitation/
retardation).
Reliability and factorial analyses
The reliability coefficient (Cronbach’s alpha) of the
PHQ-9 for the patients’ sample was 0.84. The highest
part-whole-corrected correlations between item and sum
score (rit) were obtained for items 4 (loss of energy), 2
(feeling depressed), 7 (concentration problems), and 1
(loss of interest) (Table 3). All items contributed posi-
tively to the reliability of the scale. The contribution of
the last item (suicidal ideation) was lowest, but positive
nevertheless.
Results of the 2-factorial principal components ana-
lysis (PCA) for the patients’ sample are also given in
Table 3. The theoretically assumed structure (Items 1, 2,
6, and 9 in one factor and items 3, 4, 5, 7, and 8 in the
other) was realized with one exception (item1: loss of
interest). CFA results for the total scale and for the two-
factorial structure are given in Table 4, indicating a bet-
ter fit for the latter model.
Relationship between PHQ-9 scores and other scales
The PHQ-9 items were correlated with several scales of
other questionnaires (Table 5). In the left part of Table 5,
the scales focus the affective and mental component,
while in the right part the scales also include physical
aspects.
There is a clear correspondence between item 7 (concen-
tration problems) and Cognitive functioning (r = −0.72).
Item 4 (loss of energy) is highly correlated with all scales,
including affective scales and those with physical aspects.
Among the four items (1, 2, 6, 9) assigned to Factor 2 (emo-
tional and cognitive aspect), all correlations with the Emo-
tional functioning scale are higher than those with the
EORTC fatigue scale. On the other hand, among the
five items (3, 4, 5, 7, 8) of Factor 1 (somatic aspect),
only three items (3, 4, and 5) showed higher correla-
tions with fatigue, compared with the correlations to
Emotional functioning.
Tumor-specific analyses
Table 6 shows PHQ-9 mean scores for all tumor sites
with subsample sizes of 25 and above, arranged ac-
cording to the PHQ-9 mean score. There are great
differences among the subsamples concerning age and
sex distribution. Since the PHQ-9 mean scores de-
pend on age and sex in the general population, a fair
Table 3 Factor loadings and item-test correlations for the cancer
patients
Item F1 F2 rit alpha (del)
1 Loss of interest .54 .47 .60 .82
2 Feeling depressed .49 .66 .68 .82
3 Sleep problems .75 .03 .51 .84
4 Loss of energy .78 .27 .70 .81
5 Appetite problems .58 .27 .52 .83
6 Self-blame .33 .65 .54 .83
7 Concentration problems .65 .32 .61 .82
8 Agitation/retardation .63 .21 .52 .83
9 Suicidal ideation .03 .85 .43 .84
F1, F2 factors of the principal component analysis, rit part-whole corrected
item-test correlation, alpha (del) cronbach’s alpha if item deleted;
bold: coefficients ≥ .60
Table 4 CFA results for the cancer patients
Chi2 BIC SRMR RMSEA CFI TLI
1-factorial model 494.1 32271.2 0.041 0.094 0.915 0.887
2-factorial model 302.0 32087.4 0.034 0.074 0.950 0.931
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comparison among the tumor sites requires the con-
sideration of these age and sex differences.
The linear regression analysis of the general popu-
lation’s sample yielded the following regression
equation:
PHQ ¼ 0:0367  age þ 0:310  sex þ 0:884:
Sex is to be coded with the values of 0 (males) and 1
(females). For example, the expected PHQ-9 score of a
60-years old woman is 0.0367 * 60 + 0.310 * 1 + 0.884 =
3.396. For the whole sample of the general population
(41 % women; mean age: 62.2 years), the calculation is
as follows: PHQ-9 (expected) = 0.0367 * 62.2 + 0.310 *
0.41 + 0.884 = 3.294. The column “Expected PHQ-9
Mean” in Table 6 shows these expected values for sam-
ples with the age and gender distribution of the cancer
groups. These expected means deliver the basis for the
comparison of depression burden of the different cancer
patients groups.
All groups of patients show higher mean values than the
(matched) controls, with differences ranging from 0.7
(prostate) to 5.2 (thyroid gland). The sequence of the can-
cer sites according to the PHQ-9 mean scores is similar to
the sequence according to the age-and gender-corrected
mean values (right part of Table 6). Patients with testis
Table 5 Correlations between item scores of the PHQ-9 and scale scores of other instruments in the cancer patients’ sample
Item EORTC EORTC GAD FoP EORTC EORTC EORTC
Emot. Funct. Cognit. Funct. Anxiety Fear of Progression Quality of Life Physical Funct. Fatigue
1 Loss of interest -.51 -.37 .45 .43 -.53 -.43 .49
2 Feeling depressed -.62 -.39 .60 .54 -.51 -.40 .49
3 Sleep problems -.44 -.33 .40 .41 -.38 -.34 .46
4 Loss of energy -.61 -.48 .52 .52 -.58 -.51 .70
5 Appetite problems -.42 -.32 .39 .37 -.39 -.34 .43
6 Self-blame -.49 -.36 .49 .40 -.32 -.22 .34
7 Concentration problems -.53 -.72 .48 .44 -.42 -.36 .49
8 Agitation/retardation -.46 -.48 .47 .36 -.35 -.35 .42
9 Suicidal ideation -.37 -.30 .47 .32 -.29 -.24 .27
Sum score -.74 -.62 .70 .63 -.63 -.54 .69
Bold coefficients > 0.50. All coefficients are statistically significant with p < 0.001
Table 6 PHQ-9 scores, broken down by cancer site
n PHQ-9 Mean % Females Mean age Expected PHQ-9 Mean Difference
Thyroid gland 29 8.2 72 50.6 3.0 5.2
Other Non-Hodgkin lymphoma 31 7.6 45 57.2 3.1 4.5
Ovary 41 7.6 100 63.2 3.5 4.1
Oesophagus 30 6.9 13 64.0 3.3 3.6
Breast 346 6.3 99 57.0 3.3 3.0
Non-follicular lymphoma 30 6.1 47 61.4 3.3 2.8
Pancreas 31 5.9 32 65.2 3.4 2.5
Stomach 53 5.8 34 66.9 3.4 2.4
Hodgkin lymphoma 64 5.6 56 37.1 2.4 3.2
Rectum 90 5.3 38 65.8 3.4 1.9
Kidney 119 5.2 43 65.9 3.4 1.8
Colon 196 5.0 54 70.4 3.6 1.4
Testis 35 4.9 0 35.9 2.2 2.7
Bladder 91 4.6 22 69.5 3.5 1.1
Prostate 640 4.0 0 66.9 3.3 0.7
Total 2,059 5.26 41 62.3 3.3 2.0
Expected PHQ-9 mean: mean score of a subgroup of the general population with the same age and gender distribution as the patients’ sample; Difference: Difference
between the PHQ-9 mean and the expected mean, indicating the burden of the disease
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cancer have a mean PHQ-9 score of 4.9, which is the third
lowest mean value in Table 6. Taking into account that the
patients are males and that they are relatively young, the
difference between the actual score and the expected one
(diff = 2.7) indicates a higher level of distress in this group.
A similar phenomenon can be observed for patients with
Hodgkin lymphoma.
Discussion
The first aim of this study was to test the factorial struc-
ture of the PHQ-9 administered to cancer patients. The
results of the factorial analyses demonstrate that a two-
dimensional model according to [23] performed better
than the one-dimensional model. With one exception
(item 1; loss if interest) the hypothetically assumed
structure emerged in the PCA. It is interesting to note
that the two items that were selected for the PHQ-2
(loss of interest and feeling depressed) reached good
part-whole corrected item-test-correlations (0.60 and
0.68), and that they had positive loadings in both factors
in the PCA. Together with the results of other studies
reported in the literature, we can conclude that the
PHQ-9 comprises two aspects, an affective-cognitive
component (feeling depressed, self-blame, and suicidal
ideation) and a somatic component (sleep problems, loss
of energy, and appetite problems), but that the assignment
of the remaining three items to the scales according to the
factorial analyses (loss of interest, concentration problems,
and agitation/retardation) is less clear. The reliability coef-
ficient of the total scale (Cronbach’s alpha) was good
(alpha = 0.84), and all items contributed to this scale. This
is similar to the results of other studies [38, 39]. Insuffi-
cient CFA fit indices for the total sum scale are also found
in other depression questionnaires (e.g., [40]). As long as
there is no other structure of the questionnaire that can
be reliably replicated in several studies, we believe that it
is best to maintain the sum score.
Sleep problems (item 3) and loss of energy (item 4)
were the symptoms that differed most greatly between
the cancer patients and the general population, followed
by concentration problems (item 7) and agitation/retard-
ation (item 8). As such, “classical” depression features
like feeling depressed and loss of interest, were not re-
ported to be key burdens of cancer patients half a year
after rehabilitation. Item 8 contains two contradictory
aspects of psychomotorics: agitation and retardation.
This item fitted most poorly in the Forkmann et al.
study [19] and was therefore excluded there. Clinicians
report that patients have difficulties answering this item
because of its seemingly contradictory nature. In the
PCA, the item was associated with factor 1 in the pa-
tients’ sample. It cannot be clearly interpreted. Item 9
(suicidal ideation) showed very low mean scores, and the
item-total correlations were lowest, though both
coefficients were greater than 0.40. The contribution to
the sum score of the PHQ-9 is small. However, physi-
cians may obtain relevant information when this item is
not totally denied [41]. Taking these properties of the
PHQ-9 together, it is an advantage of this short instru-
ment that it can nevertheless been used for different
purposes: (a) general screening for depression, (b) focus-
ing on two aspects of depression according to the two
factors, and (c) considering single items such as suicidal
ideation.
The mean score differences between cancer patients
and the general population were most pronounced for
the items indicating sleep problems and loss of energy.
These items belong to Factor 1 and indicate general
health problems. All nine items are heightened in the
cancer patients’ sample, but it is worth noticing that the
health-related components are most strongly affected.
The comparison between the cancer types confirmed
high degrees of depression in patients with thyroid can-
cer [42] and low degrees in those with prostate cancer
[27]. While breast cancer patients also show high mean
levels of mental distress [43], in this study breast cancer
was in the upper margin, but not at the top. Moreover,
PHQ-9 mean scores were presented for several other,
more seldom types of cancer that have not been exten-
sively examined in psycho-oncological research. In
addition to the raw PHQ-9 mean scores for the different
cancer types, we also calculated the differences between
these mean scores and the expected mean scores, based
on the age and gender distribution. There were no great
differences between raw scores and corrected scores in
the sequences (Table 6). However, for cancer types with
large proportions of males and young patients, (testis,
Hodgkin lymphoma), the burden of cancer is underesti-
mated when only simple mean scores are considered.
Regression analyses such as those performed here can
also be calculated for other questionnaires in order to
provide a basis for unbiased comparisons among sub-
groups of patients.
Some limitations of this study should be mentioned.
We examined patients half a year after discharge from a
rehabilitation clinic. Patients with a very bad prognosis
may be underrepresented or overrepresented in the sam-
ple. Though we believe that patients in a good health
state are more compliant in filling in the questionnaire,
resulting in a slight underestimation of the depression
burden in the sample, we have no information on the
non-participants. A further limitation is the limited in-
formation surrounding the health status of the respon-
dents. In addition, participants of a rehabilitation
program are not totally representative of all cancer pa-
tients. We only calculated CFA analyses for the one-
dimensional model and one two-dimensional model. It
would be possible to refine the CFA models and to
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arrive at better fit indices if several modifications were
made such as: considering sub-dimensions, correlated
error terms or removing items. However, special modifi-
cations, adapted to each data set, would not lead to
generalizable results. Some patient groups in our study
had small sample sizes, their depression mean scores
should be considered with caution. Finally, the PHQ-9 is
an economic screening instrument, which, however, is
not a sufficient substitute for a clinical diagnosis of de-
pression. Nevertheless, it can help provide aggregated in-
formation on the burden of special disease groups such
as cancer patients.
Conclusions
The results showed that the PHQ-9 is comprised of
items that measure several aspects of depression, but
that it is nevertheless useful to maintain the PHQ-9 as a
one-dimensional scale in practical applications. The re-
gression coefficients can be utilized to qualify the com-
parison among different groups of patients.
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